{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:04:15Z","timestamp":1792760655115,"version":"4.5.0"},"reference-count":113,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Human Cell"],"DOI":"10.1007\/s13577-026-01430-z","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T13:52:20Z","timestamp":1784987540000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Platelets as localized conduits of TGF-\u03b21 in the tumor microenvironment: implications for cancer progression and therapy"],"prefix":"10.1007","volume":"39","author":[{"given":"Lulu","family":"Ji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huitong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5237-1992","authenticated-orcid":false,"given":"Wei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,25]]},"reference":[{"issue":"3","key":"1430_CR1","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41569-018-0110-0","volume":"16","author":"PEJ van der Meijden","year":"2019","unstructured":"van der Meijden PEJ, Heemskerk JWM. Platelet biology and functions: new concepts and clinical perspectives. Nat Rev Cardiol. 2019;16(3):166\u201379. https:\/\/doi.org\/10.1038\/s41569-018-0110-0.","journal-title":"Nat Rev Cardiol"},{"issue":"7648","key":"1430_CR2","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/nature21706","volume":"544","author":"E Lefran\u00e7ais","year":"2017","unstructured":"Lefran\u00e7ais E, Ortiz-Mu\u00f1oz G, Caudrillier A, et al. The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors. Nature. 2017;544(7648):105\u20139. https:\/\/doi.org\/10.1038\/nature21706.","journal-title":"Nature"},{"issue":"2","key":"1430_CR3","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1161\/CIRCRESAHA.117.310795","volume":"122","author":"M Koupenova","year":"2018","unstructured":"Koupenova M, Clancy L, Corkrey HA, Freedman JE. Circulating platelets as mediators of immunity, inflammation, and thrombosis. Circ Res. 2018;122(2):337\u201351. https:\/\/doi.org\/10.1161\/CIRCRESAHA.117.310795.","journal-title":"Circ Res"},{"key":"1430_CR4","doi-asserted-by":"publisher","first-page":"16044","DOI":"10.1038\/sigtrans.2016.44","volume":"2","author":"K Shido","year":"2017","unstructured":"Shido K, Chavez D, Cao Z, Ko J, Rafii S, Ding BS. Platelets prime hematopoietic and vascular niche to drive angiocrine-mediated liver regeneration. Signal Transduct Target Ther. 2017;2:16044. https:\/\/doi.org\/10.1038\/sigtrans.2016.44.","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"1430_CR5","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41577-023-00834-4","volume":"23","author":"M Scherlinger","year":"2023","unstructured":"Scherlinger M, Richez C, Tsokos GC, Boilard E, Blanco P. The role of platelets in immune-mediated inflammatory diseases. Nat Rev Immunol. 2023;23(8):495\u2013510. https:\/\/doi.org\/10.1038\/s41577-023-00834-4.","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"1430_CR6","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.cell.2022.01.010","volume":"185","author":"M De Giovanni","year":"2022","unstructured":"De Giovanni M, Tam H, Valet C, Xu Y, Looney MR, Cyster JG. GPR35 promotes neutrophil recruitment in response to serotonin metabolite 5-HIAA. Cell. 2022;185(5):815-830.e19. https:\/\/doi.org\/10.1016\/j.cell.2022.01.010.","journal-title":"Cell"},{"issue":"2","key":"1430_CR7","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1182\/blood-2015-01-624023","volume":"126","author":"J Etulain","year":"2015","unstructured":"Etulain J, Martinod K, Wong SL, Cifuni SM, Schattner M, Wagner DD. P-selectin promotes neutrophil extracellular trap formation in mice. Blood. 2015;126(2):242\u20136. https:\/\/doi.org\/10.1182\/blood-2015-01-624023.","journal-title":"Blood"},{"issue":"1","key":"1430_CR8","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41568-023-00639-6","volume":"24","author":"S Li","year":"2024","unstructured":"Li S, Lu Z, Wu S, et al. The dynamic role of platelets in cancer progression and their therapeutic implications. Nat Rev Cancer. 2024;24(1):72\u201387. https:\/\/doi.org\/10.1038\/s41568-023-00639-6.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1430_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-01995-z","volume":"23","author":"P Yu","year":"2024","unstructured":"Yu P, Han Y, Meng L, et al. The incorporation of acetylated LAP-TGF-\u03b21 proteins into exosomes promotes TNBC cell dissemination in lung micro-metastasis. Mol Cancer. 2024;23(1):82. https:\/\/doi.org\/10.1186\/s12943-024-01995-z.","journal-title":"Mol Cancer"},{"issue":"1","key":"1430_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01349-6","volume":"15","author":"X Shi","year":"2022","unstructured":"Shi X, Yang J, Deng S, et al. TGF-\u03b2 signaling in the tumor metabolic microenvironment and targeted therapies. J Hematol Oncol. 2022;15(1):135. https:\/\/doi.org\/10.1186\/s13045-022-01349-6.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"1430_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s43556-026-00403-w","volume":"7","author":"J Liu","year":"2026","unstructured":"Liu J, Wang Y, Tang C, et al. TGF-\u03b2 in tumor development and progression: mechanisms and therapeutics. Mol Biomed. 2026;7(1):9. https:\/\/doi.org\/10.1186\/s43556-026-00403-w.","journal-title":"Mol Biomed"},{"issue":"1","key":"1430_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41571-020-0403-1","volume":"18","author":"R Derynck","year":"2021","unstructured":"Derynck R, Turley SJ, Akhurst RJ. TGF\u03b2 biology in cancer progression and immunotherapy. Nat Rev Clin Oncol. 2021;18(1):9\u201334. https:\/\/doi.org\/10.1038\/s41571-020-0403-1.","journal-title":"Nat Rev Clin Oncol"},{"issue":"16","key":"1430_CR13","doi-asserted-by":"publisher","first-page":"15388","DOI":"10.1021\/acsnano.3c00295","volume":"17","author":"L Luo","year":"2023","unstructured":"Luo L, Zhang B, Tao F, et al. Perfluorotributylamine-loaded albumin nanoparticles downregulate platelet-derived TGF\u03b2 to inhibit tumor metastasis. ACS Nano. 2023;17(16):15388\u2013400. https:\/\/doi.org\/10.1021\/acsnano.3c00295.","journal-title":"ACS Nano"},{"issue":"22","key":"1430_CR14","doi-asserted-by":"publisher","first-page":"6200","DOI":"10.1016\/j.cell.2024.08.036","volume":"187","author":"M Jin","year":"2024","unstructured":"Jin M, Seed RI, Cai G, et al. Dynamic allostery drives autocrine and paracrine TGF-\u03b2 signaling. Cell. 2024;187(22):6200-6219.e23. https:\/\/doi.org\/10.1016\/j.cell.2024.08.036.","journal-title":"Cell"},{"issue":"13","key":"1430_CR15","doi-asserted-by":"publisher","DOI":"10.1172\/JCI184422","volume":"135","author":"L Kalfeist","year":"2025","unstructured":"Kalfeist L, Ledys F, Petit S, et al. Co-targeting TGF-\u03b2 and PD-L1 sensitizes triple-negative breast cancer to experimental immunogenic cisplatin-eribulin chemotherapy doublet. J Clin Invest. 2025;135(13):e184422. https:\/\/doi.org\/10.1172\/JCI184422.","journal-title":"J Clin Invest"},{"issue":"1","key":"1430_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-024-03001-2","volume":"43","author":"O Le Chapelain","year":"2024","unstructured":"Le Chapelain O, Jadoui S, Gros A, et al. The localization, origin, and impact of platelets in the tumor microenvironment are tumor type-dependent. J Exp Clin Cancer Res. 2024;43(1):84. https:\/\/doi.org\/10.1186\/s13046-024-03001-2.","journal-title":"J Exp Clin Cancer Res"},{"key":"1430_CR17","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-032713-120257","volume":"32","author":"MA Travis","year":"2014","unstructured":"Travis MA, Sheppard D. TGF-\u03b2 activation and function in immunity. Annu Rev Immunol. 2014;32:51\u201382. https:\/\/doi.org\/10.1146\/annurev-immunol-032713-120257.","journal-title":"Annu Rev Immunol"},{"issue":"5","key":"1430_CR18","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.ccr.2011.09.009","volume":"20","author":"M Labelle","year":"2011","unstructured":"Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell. 2011;20(5):576\u201390. https:\/\/doi.org\/10.1016\/j.ccr.2011.09.009.","journal-title":"Cancer Cell"},{"issue":"1","key":"1430_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s41232-022-00225-7","volume":"42","author":"M Kobayashi","year":"2022","unstructured":"Kobayashi M, Fujiwara K, Takahashi K, et al. Transforming growth factor-\u03b2-induced secretion of extracellular vesicles from oral cancer cells evokes endothelial barrier instability via endothelial-mesenchymal transition. Inflamm Regen. 2022;42(1):38. https:\/\/doi.org\/10.1186\/s41232-022-00225-7.","journal-title":"Inflamm Regen"},{"issue":"1","key":"1430_CR20","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1515\/med-2022-0432","volume":"17","author":"Y Shi","year":"2022","unstructured":"Shi Y, Li X, Yang J. Cx43 upregulation in HUVECs under stretch via TGF-\u03b21 and cytoskeletal network. Open Med. 2022;17(1):463\u201374. https:\/\/doi.org\/10.1515\/med-2022-0432.","journal-title":"Open Med"},{"key":"1430_CR21","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.semcancer.2023.04.007","volume":"92","author":"T Watabe","year":"2023","unstructured":"Watabe T, Takahashi K, Pietras K, Yoshimatsu Y. Roles of TGF-\u03b2 signals in tumor microenvironment via regulation of the formation and plasticity of vascular system. Semin Cancer Biol. 2023;92:130\u20138. https:\/\/doi.org\/10.1016\/j.semcancer.2023.04.007.","journal-title":"Semin Cancer Biol"},{"issue":"6","key":"1430_CR22","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.ccell.2018.03.002","volume":"33","author":"M Haemmerle","year":"2018","unstructured":"Haemmerle M, Stone RL, Menter DG, Afshar-Kharghan V, Sood AK. The platelet lifeline to cancer: challenges and opportunities. Cancer Cell. 2018;33(6):965\u201383. https:\/\/doi.org\/10.1016\/j.ccell.2018.03.002.","journal-title":"Cancer Cell"},{"key":"1430_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6256","volume":"5","author":"LX Yu","year":"2014","unstructured":"Yu LX, Yan L, Yang W, et al. Platelets promote tumour metastasis via interaction between TLR4 and tumour cell-released high-mobility group box1 protein. Nat Commun. 2014;5:5256. https:\/\/doi.org\/10.1038\/ncomms6256.","journal-title":"Nat Commun"},{"issue":"12","key":"1430_CR24","doi-asserted-by":"publisher","first-page":"4638","DOI":"10.1172\/JCI81660","volume":"125","author":"S Vogel","year":"2015","unstructured":"Vogel S, Bodenstein R, Chen Q, et al. Platelet-derived HMGB1 is a critical mediator of thrombosis. J Clin Invest. 2015;125(12):4638\u201354. https:\/\/doi.org\/10.1172\/JCI81660.","journal-title":"J Clin Invest"},{"issue":"11","key":"1430_CR25","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1161\/CIRCRESAHA.122.321861","volume":"132","author":"T Dudiki","year":"2023","unstructured":"Dudiki T, Veleeparambil M, Zhevlakova I, et al. Mechanism of tumor-platelet communications in cancer. Circ Res. 2023;132(11):1447\u201361. https:\/\/doi.org\/10.1161\/CIRCRESAHA.122.321861.","journal-title":"Circ Res"},{"issue":"6","key":"1430_CR26","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1016\/j.cell.2025.01.025","volume":"188","author":"S Lucotti","year":"2025","unstructured":"Lucotti S, Ogitani Y, Kenific CM, et al. Extracellular vesicles from the lung pro-thrombotic niche drive cancer-associated thrombosis and metastasis via integrin beta 2. Cell. 2025;188(6):1642-1661.e24. https:\/\/doi.org\/10.1016\/j.cell.2025.01.025.","journal-title":"Cell"},{"issue":"1","key":"1430_CR27","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1172\/JCI122955","volume":"129","author":"J Rayes","year":"2019","unstructured":"Rayes J, Watson SP, Nieswandt B. Functional significance of the platelet immune receptors GPVI and CLEC-2. J Clin Invest. 2019;129(1):12\u201323. https:\/\/doi.org\/10.1172\/JCI122955.","journal-title":"J Clin Invest"},{"issue":"14","key":"1430_CR28","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1182\/blood.2019002649","volume":"135","author":"E Mammadova-Bach","year":"2020","unstructured":"Mammadova-Bach E, Gil-Pulido J, Sarukhanyan E, et al. Platelet glycoprotein VI promotes metastasis through interaction with cancer cell-derived galectin-3. Blood. 2020;135(14):1146\u201360. https:\/\/doi.org\/10.1182\/blood.2019002649.","journal-title":"Blood"},{"issue":"1","key":"1430_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0669-2","volume":"11","author":"M Schlesinger","year":"2018","unstructured":"Schlesinger M. Role of platelets and platelet receptors in cancer metastasis. J Hematol Oncol. 2018;11(1):125. https:\/\/doi.org\/10.1186\/s13045-018-0669-2.","journal-title":"J Hematol Oncol"},{"issue":"22","key":"1430_CR30","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1182\/blood-2017-09-742650","volume":"131","author":"Y Chen","year":"2018","unstructured":"Chen Y, Ruggeri ZM, Du X. 14-3-3 proteins in platelet biology and glycoprotein Ib-IX signaling. Blood. 2018;131(22):2436\u201348. https:\/\/doi.org\/10.1182\/blood-2017-09-742650.","journal-title":"Blood"},{"issue":"2","key":"1430_CR31","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/cac2.12637","volume":"45","author":"LL Yao","year":"2025","unstructured":"Yao LL, Qin WT, Hu LP, et al. Reciprocal tumor-platelet interaction through the EPHB1-EFNB1 axis in the liver metastatic niche promotes metastatic tumor outgrowth in pancreatic ductal adenocarcinoma. Cancer Commun. 2025;45(2):143\u201366. https:\/\/doi.org\/10.1002\/cac2.12637.","journal-title":"Cancer Commun"},{"issue":"4","key":"1430_CR32","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1111\/febs.70279","volume":"293","author":"M Genitoni","year":"2026","unstructured":"Genitoni M, Merolle L, Razzoli A, et al. TGF\u03b2 enhances platelet-breast-cancer-cell interaction and promotes platelet aggregation. FEBS J. 2026;293(4):1045\u201365. https:\/\/doi.org\/10.1111\/febs.70279.","journal-title":"FEBS J"},{"issue":"6","key":"1430_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70217","volume":"6","author":"K Zhou","year":"2025","unstructured":"Zhou K, Li Q, Xia Y, et al. Glycoprotein Ib\u03b1-dependent platelet activation is essential for tumor cell-platelet interaction and experimental metastasis. MedComm. 2025;6(6):e70217. https:\/\/doi.org\/10.1002\/mco2.70217.","journal-title":"MedComm"},{"issue":"12","key":"1430_CR34","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1161\/01.RES.0000251742.71301.16","volume":"99","author":"S Offermanns","year":"2006","unstructured":"Offermanns S. Activation of platelet function through G protein-coupled receptors. Circ Res. 2006;99(12):1293\u2013304. https:\/\/doi.org\/10.1161\/01.RES.0000251742.71301.16.","journal-title":"Circ Res"},{"issue":"12","key":"1430_CR35","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1182\/blood.2024025320","volume":"146","author":"F Swieringa","year":"2025","unstructured":"Swieringa F, Heemskerk JWM, Assinger A. Platelet activation and signaling in thrombus formation. Blood. 2025;146(12):1400\u201311. https:\/\/doi.org\/10.1182\/blood.2024025320.","journal-title":"Blood"},{"issue":"3","key":"1430_CR36","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.3390\/ijms24032519","volume":"24","author":"A Dandamudi","year":"2023","unstructured":"Dandamudi A, Akbar H, Cancelas J, Zheng Y. Rho GTPase signaling in platelet regulation and implication for antiplatelet therapies. Int J Mol Sci. 2023;24(3):2519. https:\/\/doi.org\/10.3390\/ijms24032519.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"1430_CR37","doi-asserted-by":"publisher","first-page":"5138","DOI":"10.7150\/thno.110120","volume":"15","author":"J Qu","year":"2025","unstructured":"Qu J, Li J, Wang H, Lan J, Huo Z, Li X. Decoding the role of microtubules: a trafficking road for vesicle. Theranostics. 2025;15(11):5138\u201352. https:\/\/doi.org\/10.7150\/thno.110120.","journal-title":"Theranostics"},{"issue":"1","key":"1430_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42497-8","volume":"14","author":"KC Courtney","year":"2023","unstructured":"Courtney KC, Mandal T, Mehta N, et al. Synaptotagmin-7 outperforms synaptotagmin-1 to promote the formation of large, stable fusion pores via robust membrane penetration. Nat Commun. 2023;14(1):7761. https:\/\/doi.org\/10.1038\/s41467-023-42497-8.","journal-title":"Nat Commun"},{"key":"1430_CR39","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1146\/annurev-biochem-081820-103615","volume":"90","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Hughson FM. Chaperoning SNARE folding and assembly. Annu Rev Biochem. 2021;90:581\u2013603. https:\/\/doi.org\/10.1146\/annurev-biochem-081820-103615.","journal-title":"Annu Rev Biochem"},{"issue":"7351","key":"1430_CR40","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nature10152","volume":"474","author":"M Shi","year":"2011","unstructured":"Shi M, Zhu J, Wang R, et al. Latent TGF-\u03b2 structure and activation. Nature. 2011;474(7351):343\u20139. https:\/\/doi.org\/10.1038\/nature10152.","journal-title":"Nature"},{"issue":"19","key":"1430_CR41","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.1016\/j.cell.2023.07.036","volume":"186","author":"J Massagu\u00e9","year":"2023","unstructured":"Massagu\u00e9 J, Sheppard D. TGF-\u03b2 signaling in health and disease. Cell. 2023;186(19):4007\u201337. https:\/\/doi.org\/10.1016\/j.cell.2023.07.036.","journal-title":"Cell"},{"issue":"5","key":"1430_CR42","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1182\/blood.2022017097","volume":"141","author":"S Lecomte","year":"2023","unstructured":"Lecomte S, Devreux J, de Streel G, et al. Therapeutic activity of GARP:TGF-\u03b21 blockade in murine primary myelofibrosis. Blood. 2023;141(5):490\u2013502. https:\/\/doi.org\/10.1182\/blood.2022017097.","journal-title":"Blood"},{"issue":"525","key":"1430_CR43","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aay4860","volume":"12","author":"A Metelli","year":"2020","unstructured":"Metelli A, Wu BX, Riesenberg B, et al. Thrombin contributes to cancer immune evasion via proteolysis of platelet-bound GARP to activate LTGF-\u03b2. Sci Transl Med. 2020;12(525):eaay4860. https:\/\/doi.org\/10.1126\/scitranslmed.aay4860.","journal-title":"Sci Transl Med"},{"issue":"32","key":"1430_CR44","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202501078","volume":"12","author":"WN Lee","year":"2025","unstructured":"Lee WN, Li J, Chen NP, Yu CH. Kindlin regulates mechanosensitive activation and adhesion assembly of integrin beta6. Adv Sci. 2025;12(32):e01078. https:\/\/doi.org\/10.1002\/advs.202501078.","journal-title":"Adv Sci"},{"issue":"18","key":"1430_CR45","doi-asserted-by":"publisher","first-page":"5611","DOI":"10.1158\/1078-0432.CCR-16-3272","volume":"23","author":"Q Hu","year":"2017","unstructured":"Hu Q, Hisamatsu T, Haemmerle M, et al. Role of platelet-derived Tgf\u03b21 in the progression of ovarian cancer. Clin Cancer Res. 2017;23(18):5611\u201321. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-3272.","journal-title":"Clin Cancer Res"},{"key":"1430_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217161","volume":"600","author":"M Lu","year":"2024","unstructured":"Lu M, Gong X, Zhang YM, et al. Platelets promote primary hepatocellular carcinoma metastasis through TGF-\u03b21-mediated cancer cell autophagy. Cancer Lett. 2024;600:217161. https:\/\/doi.org\/10.1016\/j.canlet.2024.217161.","journal-title":"Cancer Lett"},{"issue":"11","key":"1430_CR47","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aai7911","volume":"2","author":"S Rachidi","year":"2017","unstructured":"Rachidi S, Metelli A, Riesenberg B, et al. Platelets subvert T cell immunity against cancer via GARP-TGF\u03b2 axis. Sci Immunol. 2017;2(11):eaai7911. https:\/\/doi.org\/10.1126\/sciimmunol.aai7911.","journal-title":"Sci Immunol"},{"key":"1430_CR48","doi-asserted-by":"publisher","first-page":"8251","DOI":"10.2147\/OTT.S181673","volume":"11","author":"Q Wang","year":"2018","unstructured":"Wang Q, Li Z, Sun L, et al. Platelets enhance the ability of bone-marrow mesenchymal stem cells to promote cancer metastasis. Onco Targets Ther. 2018;11:8251\u201363. https:\/\/doi.org\/10.2147\/OTT.S181673.","journal-title":"Onco Targets Ther"},{"key":"1430_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216902","volume":"591","author":"Q Shi","year":"2024","unstructured":"Shi Q, Xu J, Chen C, et al. Direct contact between tumor cells and platelets initiates a FAK-dependent F3\/TGF-\u03b2 positive feedback loop that promotes tumor progression and EMT in osteosarcoma. Cancer Lett. 2024;591:216902. https:\/\/doi.org\/10.1016\/j.canlet.2024.216902.","journal-title":"Cancer Lett"},{"issue":"4","key":"1430_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2025.167734","volume":"1871","author":"G Luo","year":"2025","unstructured":"Luo G, Zhu S, He L, et al. Platelets promote metastasis of intrahepatic cholangiocarcinoma through activation of TGF-\u03b2\/Smad2 pathway. Biochim Biophysica Acta (BBA) - Mol Basis Dis. 2025;1871(4):167734. https:\/\/doi.org\/10.1016\/j.bbadis.2025.167734.","journal-title":"Biochim Biophysica Acta (BBA) - Mol Basis Dis"},{"issue":"19","key":"1430_CR51","doi-asserted-by":"publisher","first-page":"7775","DOI":"10.1158\/0008-5472.CAN-09-2123","volume":"69","author":"HG Kopp","year":"2009","unstructured":"Kopp HG, Placke T, Salih HR. Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. Cancer Res. 2009;69(19):7775\u201383. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-2123.","journal-title":"Cancer Res"},{"issue":"6","key":"1430_CR52","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nrc2853","volume":"10","author":"H Ikushima","year":"2010","unstructured":"Ikushima H, Miyazono K. TGF\u03b2 signalling: a complex web in cancer progression. Nat Rev Cancer. 2010;10(6):415\u201324. https:\/\/doi.org\/10.1038\/nrc2853.","journal-title":"Nat Rev Cancer"},{"issue":"15","key":"1430_CR53","doi-asserted-by":"publisher","first-page":"3797","DOI":"10.1158\/0008-5472.CAN-18-2019","volume":"79","author":"HW Yeh","year":"2019","unstructured":"Yeh HW, Lee SS, Chang CY, Lang YD, Jou YS. A new switch for TGF\u03b2 in cancer. Cancer Res. 2019;79(15):3797\u2013805. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-2019.","journal-title":"Cancer Res"},{"issue":"16","key":"1430_CR54","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.1158\/0008-5472.CAN-24-1970","volume":"85","author":"GZ Murimwa","year":"2025","unstructured":"Murimwa GZ, Williams NE, Alzhanova D, et al. SMAD4 deficiency promotes pancreatic cancer progression and confers susceptibility to TGF\u03b2 inhibition. Cancer Res. 2025;85(16):2987\u201396. https:\/\/doi.org\/10.1158\/0008-5472.CAN-24-1970.","journal-title":"Cancer Res"},{"issue":"1","key":"1430_CR55","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41392-020-00436-9","volume":"6","author":"S Liu","year":"2021","unstructured":"Liu S, Ren J, Ten Dijke P. Targeting TGF\u03b2 signal transduction for cancer therapy. Signal Transduct Target Ther. 2021;6(1):8. https:\/\/doi.org\/10.1038\/s41392-020-00436-9.","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"1430_CR56","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/s1097-2765(03)00386-1","volume":"12","author":"MJ Goumans","year":"2003","unstructured":"Goumans MJ, Valdimarsdottir G, Itoh S, et al. Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGF\u03b2\/ALK5 signaling. Mol Cell. 2003;12(4):817\u201328. https:\/\/doi.org\/10.1016\/s1097-2765(03)00386-1.","journal-title":"Mol Cell"},{"issue":"1","key":"1430_CR57","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1158\/0008-5472.CAN-24-2324","volume":"85","author":"YW Luo","year":"2025","unstructured":"Luo YW, Fang Y, Zeng HX, et al. HIF1\u03b1 counteracts TGF\u03b21-driven TSP1 expression in endothelial cells to stimulate angiogenesis in the hypoxic tumor microenvironment. Cancer Res. 2025;85(1):69\u201383. https:\/\/doi.org\/10.1158\/0008-5472.CAN-24-2324.","journal-title":"Cancer Res"},{"issue":"11","key":"1430_CR58","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/j.medj.2021.10.002","volume":"2","author":"MN O'Connor","year":"2021","unstructured":"O\u2019Connor MN, Kallenberg DM, Camilli C, et al. LRG1 destabilizes tumor vessels and restricts immunotherapeutic potency. Med. 2021;2(11):1231-1252.e10. https:\/\/doi.org\/10.1016\/j.medj.2021.10.002.","journal-title":"Med"},{"issue":"1","key":"1430_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-025-01688-0","volume":"18","author":"H Jia","year":"2025","unstructured":"Jia H, Chen X, Zhang L, Chen M. Cancer associated fibroblasts in cancer development and therapy. J Hematol Oncol. 2025;18(1):36. https:\/\/doi.org\/10.1186\/s13045-025-01688-0.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"1430_CR60","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s11605-021-05087-x","volume":"26","author":"K Trebska-McGowan","year":"2022","unstructured":"Trebska-McGowan K, Chaib M, Alvarez MA, et al. TGF-\u03b2 alters the proportion of infiltrating immune cells in a pancreatic ductal adenocarcinoma. J Gastrointest Surg. 2022;26(1):113\u201321. https:\/\/doi.org\/10.1007\/s11605-021-05087-x.","journal-title":"J Gastrointest Surg"},{"key":"1430_CR61","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.694145","volume":"11","author":"S Bao","year":"2021","unstructured":"Bao S, Jiang X, Jin S, Tu P, Lu J. TGF-\u03b21 induces immune escape by enhancing PD-1 and CTLA-4 expression on T lymphocytes in hepatocellular carcinoma. Front Oncol. 2021;11:694145. https:\/\/doi.org\/10.3389\/fonc.2021.694145.","journal-title":"Front Oncol"},{"issue":"9","key":"1430_CR62","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005433","volume":"10","author":"A Li","year":"2022","unstructured":"Li A, Chang Y, Song NJ, et al. Selective targeting of GARP-LTGF\u03b2 axis in the tumor microenvironment augments PD-1 blockade via enhancing CD8+ T cell antitumor immunity. J Immunother Cancer. 2022;10(9):e005433. https:\/\/doi.org\/10.1136\/jitc-2022-005433.","journal-title":"J Immunother Cancer"},{"issue":"69","key":"1430_CR63","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abi4613","volume":"7","author":"JM Moreau","year":"2022","unstructured":"Moreau JM, Velegraki M, Bolyard C, Rosenblum MD, Li Z. Transforming growth factor-\u03b21 in regulatory T cell biology. Sci Immunol. 2022;7(69):eabi4613. https:\/\/doi.org\/10.1126\/sciimmunol.abi4613.","journal-title":"Sci Immunol"},{"issue":"13","key":"1430_CR64","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1158\/0008-5472.CAN-22-3009","volume":"83","author":"F Ye","year":"2023","unstructured":"Ye F, Cai Z, Wang B, et al. TGF\u03b2 antagonizes IFN\u03b3-mediated adaptive immune evasion via activation of the AKT-Smad3-SHP1 axis in lung adenocarcinoma. Cancer Res. 2023;83(13):2262\u201377. https:\/\/doi.org\/10.1158\/0008-5472.CAN-22-3009.","journal-title":"Cancer Res"},{"issue":"1","key":"1430_CR65","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1182\/blood.2023022738","volume":"144","author":"L Wang","year":"2024","unstructured":"Wang L, Wang H, Zhu M, et al. Platelet-derived TGF-\u03b21 induces functional reprogramming of myeloid-derived suppressor cells in immune thrombocytopenia. Blood. 2024;144(1):99\u2013112. https:\/\/doi.org\/10.1182\/blood.2023022738.","journal-title":"Blood"},{"issue":"19","key":"1430_CR66","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1038\/s41388-023-02674-x","volume":"42","author":"A Liu","year":"2023","unstructured":"Liu A, Yu C, Qiu C, et al. PRMT5 methylating SMAD4 activates TGF-\u03b2 signaling and promotes colorectal cancer metastasis. Oncogene. 2023;42(19):1572\u201384. https:\/\/doi.org\/10.1038\/s41388-023-02674-x.","journal-title":"Oncogene"},{"issue":"5","key":"1430_CR67","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1007\/s10620-025-08890-7","volume":"70","author":"Y Liu","year":"2025","unstructured":"Liu Y, Mo W, Sun W, et al. NFAT2 induces tumor cell proliferation and metastasis by acting as a transcriptional co-activator of the TGF-\u03b21\/SMAD signaling pathway and inducing the epithelial-mesenchymal transition in liver cancer. Dig Dis Sci. 2025;70(5):1799\u2013812. https:\/\/doi.org\/10.1007\/s10620-025-08890-7.","journal-title":"Dig Dis Sci"},{"issue":"6","key":"1430_CR68","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s00432-012-1363-3","volume":"139","author":"H Zhang","year":"2013","unstructured":"Zhang H, Liu L, Wang Y, et al. KLF8 involves in TGF-beta-induced EMT and promotes invasion and migration in gastric cancer cells. J Cancer Res Clin Oncol. 2013;139(6):1033\u201342. https:\/\/doi.org\/10.1007\/s00432-012-1363-3.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"9","key":"1430_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0877-2","volume":"9","author":"T Li","year":"2018","unstructured":"Li T, Huang H, Shi G, et al. TGF-\u03b21-SOX9 axis-inducible COL10A1 promotes invasion and metastasis in gastric cancer via epithelial-to-mesenchymal transition. Cell Death Dis. 2018;9(9):849. https:\/\/doi.org\/10.1038\/s41419-018-0877-2.","journal-title":"Cell Death Dis"},{"issue":"23","key":"1430_CR70","doi-asserted-by":"publisher","first-page":"6892","DOI":"10.7150\/jca.48426","volume":"11","author":"Q Liu","year":"2020","unstructured":"Liu Q, Zheng S, Chen Y, et al. TGF-\u03b21-induced upregulation of MALAT1 promotes Kazakh\u2019s esophageal squamous cell carcinoma invasion by EMT. J Cancer. 2020;11(23):6892\u2013901. https:\/\/doi.org\/10.7150\/jca.48426.","journal-title":"J Cancer"},{"issue":"17","key":"1430_CR71","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202401427R","volume":"38","author":"Z Tang","year":"2024","unstructured":"Tang Z, Zhang D, Yao C, et al. TIPE2 inhibits the migration and invasion of epithelial ovarian cancer cells by targeting Smad2 to reverse TGF-\u03b21-induced EMT. FASEB J. 2024;38(17):e70045. https:\/\/doi.org\/10.1096\/fj.202401427R.","journal-title":"FASEB J"},{"issue":"3","key":"1430_CR72","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/1878-0261.12162","volume":"12","author":"Y Zhao","year":"2018","unstructured":"Zhao Y, Ma J, Fan Y, et al. TGF-\u03b2 transactivates EGFR and facilitates breast cancer migration and invasion through canonical Smad3 and ERK\/Sp1 signaling pathways. Mol Oncol. 2018;12(3):305\u201321. https:\/\/doi.org\/10.1002\/1878-0261.12162.","journal-title":"Mol Oncol"},{"issue":"1","key":"1430_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2022.113195","volume":"417","author":"BC Jena","year":"2022","unstructured":"Jena BC, Das CK, Banerjee I, et al. TGF-\u03b21 induced autophagy in cancer associated fibroblasts during hypoxia contributes EMT and glycolysis via MCT4 upregulation. Exp Cell Res. 2022;417(1):113195. https:\/\/doi.org\/10.1016\/j.yexcr.2022.113195.","journal-title":"Exp Cell Res"},{"issue":"1","key":"1430_CR74","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04303-3","volume":"21","author":"Q Ping","year":"2023","unstructured":"Ping Q, Wang C, Cheng X, et al. TGF-\u03b21 dominates stromal fibroblast-mediated EMT via the FAP\/VCAN axis in bladder cancer cells. J Transl Med. 2023;21(1):475. https:\/\/doi.org\/10.1186\/s12967-023-04303-3.","journal-title":"J Transl Med"},{"key":"1430_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2024.177218","volume":"988","author":"VK Deb","year":"2025","unstructured":"Deb VK, Chauhan N, Jain U. Deciphering TGF-\u03b21\u2019s role in drug resistance and leveraging plant bioactives for cancer therapy. Eur J Pharmacol. 2025;988:177218. https:\/\/doi.org\/10.1016\/j.ejphar.2024.177218.","journal-title":"Eur J Pharmacol"},{"issue":"18","key":"1430_CR76","doi-asserted-by":"publisher","first-page":"9420","DOI":"10.1039\/d4fo02346c","volume":"15","author":"YL Jiang","year":"2024","unstructured":"Jiang YL, Li X, Tan YW, et al. Docosahexaenoic acid inhibits the invasion and migration of colorectal cancer by reversing EMT through the TGF-\u03b21\/Smad signaling pathway. Food Funct. 2024;15(18):9420\u201333. https:\/\/doi.org\/10.1039\/d4fo02346c.","journal-title":"Food Funct"},{"issue":"4","key":"1430_CR77","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.7150\/jca.103757","volume":"16","author":"C Zhong","year":"2025","unstructured":"Zhong C, Wang W, Yao Y, et al. TGF-\u03b2 secreted by cancer cells-platelets interaction activates cancer metastasis potential by inducing metabolic reprogramming and bioenergetic adaptation. J Cancer. 2025;16(4):1310\u201323. https:\/\/doi.org\/10.7150\/jca.103757.","journal-title":"J Cancer"},{"issue":"1","key":"1430_CR78","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-62487-2","volume":"16","author":"J Solarz","year":"2025","unstructured":"Solarz J, Soukaseum C, Fr\u00e9mont S, et al. F-actin disassembly by the oxidoreductase MICAL1 promotes mechano-dependent VWF-GPIb\u03b1 interaction in platelets. Nat Commun. 2025;16(1):7375. https:\/\/doi.org\/10.1038\/s41467-025-62487-2.","journal-title":"Nat Commun"},{"issue":"6","key":"1430_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2025.112517","volume":"28","author":"Y Ikeda","year":"2025","unstructured":"Ikeda Y, Kondo M, Suehiro JI, et al. A tumor-microvessel on-a-chip reveals a mechanism for cancer cell cluster intravasation. iScience. 2025;28(6):112517. https:\/\/doi.org\/10.1016\/j.isci.2025.112517.","journal-title":"iScience"},{"issue":"12","key":"1430_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.111502","volume":"27","author":"K Hanada","year":"2024","unstructured":"Hanada K, Saito Y, Takagi T, et al. Reduced lung metastasis in endothelial cell-specific transforming growth factor \u03b2 type II receptor-deficient mice with decreased CD44 expression. iScience. 2024;27(12):111502. https:\/\/doi.org\/10.1016\/j.isci.2024.111502.","journal-title":"iScience"},{"issue":"1","key":"1430_CR81","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01937-7","volume":"9","author":"Y Wang","year":"2024","unstructured":"Wang Y, Jia J, Wang F, et al. Pre-metastatic niche: formation, characteristics and therapeutic implication. Signal Transduct Target Ther. 2024;9(1):236. https:\/\/doi.org\/10.1038\/s41392-024-01937-7.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"1430_CR82","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12943-019-0995-1","volume":"18","author":"Y Guo","year":"2019","unstructured":"Guo Y, Ji X, Liu J, et al. Effects of exosomes on pre-metastatic niche formation in tumors. Mol Cancer. 2019;18(1):39. https:\/\/doi.org\/10.1186\/s12943-019-0995-1.","journal-title":"Mol Cancer"},{"issue":"18","key":"1430_CR83","doi-asserted-by":"publisher","first-page":"4751","DOI":"10.1158\/0008-5472.CAN-20-3941","volume":"81","author":"R Sato","year":"2021","unstructured":"Sato R, Imamura K, Semba T, et al. TGF\u03b2 signaling activated by cancer-associated fibroblasts determines the histological signature of lung adenocarcinoma. Cancer Res. 2021;81(18):4751\u201365. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-3941.","journal-title":"Cancer Res"},{"issue":"2","key":"1430_CR84","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s10555-017-9679-8","volume":"36","author":"P Gresele","year":"2017","unstructured":"Gresele P, Momi S, Malvestiti M, Sebastiano M. Platelet-targeted pharmacologic treatments as anti-cancer therapy. Cancer Metastasis Rev. 2017;36(2):331\u201355. https:\/\/doi.org\/10.1007\/s10555-017-9679-8.","journal-title":"Cancer Metastasis Rev"},{"issue":"3","key":"1430_CR85","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0090353","volume":"9","author":"JC Morris","year":"2014","unstructured":"Morris JC, Tan AR, Olencki TE, et al. Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGF\u03b2) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. PLoS ONE. 2014;9(3):e90353. https:\/\/doi.org\/10.1371\/journal.pone.0090353.","journal-title":"PLoS ONE"},{"issue":"11","key":"1430_CR86","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007353","volume":"11","author":"TM Bauer","year":"2023","unstructured":"Bauer TM, Santoro A, Lin CC, et al. Phase I\/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-\u03b2 monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors. J Immunother Cancer. 2023;11(11):e007353. https:\/\/doi.org\/10.1136\/jitc-2023-007353.","journal-title":"J Immunother Cancer"},{"issue":"3","key":"1430_CR87","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1177\/1091581821998945","volume":"40","author":"BT Welsh","year":"2021","unstructured":"Welsh BT, Faucette R, Bilic S, et al. Nonclinical development of SRK-181: an anti-latent TGF\u03b21 monoclonal antibody for the treatment of locally advanced or metastatic solid tumors. Int J Toxicol. 2021;40(3):226\u201341. https:\/\/doi.org\/10.1177\/1091581821998945.","journal-title":"Int J Toxicol"},{"issue":"3","key":"1430_CR88","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1038\/s41591-025-04157-w","volume":"32","author":"TA Yap","year":"2026","unstructured":"Yap TA, Sweis RF, Vaishampayan U, et al. Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trial. Nat Med. 2026;32(3):992\u20131001. https:\/\/doi.org\/10.1038\/s41591-025-04157-w.","journal-title":"Nat Med"},{"issue":"9","key":"1430_CR89","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/S1470-2045(22)00446-6","volume":"23","author":"T Yamazaki","year":"2022","unstructured":"Yamazaki T, Gunderson AJ, Gilchrist M, et al. Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial. Lancet Oncol. 2022;23(9):1189\u2013200. https:\/\/doi.org\/10.1016\/S1470-2045(22)00446-6.","journal-title":"Lancet Oncol"},{"issue":"8","key":"1430_CR90","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1158\/1078-0432.CCR-23-2823","volume":"30","author":"JH Ahn","year":"2024","unstructured":"Ahn JH, Lee J, Park C, et al. Clinical activity of TGF-\u03b2 inhibitor vactosertib in combination with imatinib in desmoid tumors: a multicenter phase Ib\/II study. Clin Cancer Res. 2024;30(8):1457\u201365. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-2823.","journal-title":"Clin Cancer Res"},{"key":"1430_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2025.101242","volume":"81","author":"E Rahimian","year":"2025","unstructured":"Rahimian E, Koochak M, Traikov S, et al. A quiescence-like\/TGF-\u03b21-specific CRISPRi screen reveals drug uptake transporters as secondary targets of kinase inhibitors in AML. Drug Resist Updat. 2025;81:101242. https:\/\/doi.org\/10.1016\/j.drup.2025.101242.","journal-title":"Drug Resist Updat"},{"issue":"16","key":"1430_CR92","doi-asserted-by":"publisher","first-page":"3424","DOI":"10.1158\/1078-0432.CCR-25-0085","volume":"31","author":"LQ Tang","year":"2025","unstructured":"Tang LQ, Liu SL, Yang MH, et al. GFH018 and toripalimab combination therapy for previously treated recurrent or metastatic nasopharyngeal carcinoma: results from a phase Ib\/II study. Clin Cancer Res. 2025;31(16):3424\u201332. https:\/\/doi.org\/10.1158\/1078-0432.CCR-25-0085.","journal-title":"Clin Cancer Res"},{"issue":"24","key":"1430_CR93","doi-asserted-by":"publisher","first-page":"6666","DOI":"10.1158\/1078-0432.CCR-21-1504","volume":"27","author":"TA Yap","year":"2021","unstructured":"Yap TA, Vieito M, Baldini C, et al. First-in-human phase I study of a next-generation, oral, TGF\u03b2 receptor 1 inhibitor, LY3200882, in patients with advanced cancer. Clin Cancer Res. 2021;27(24):6666\u201376. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-1504.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1430_CR94","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41421-022-00459-2","volume":"8","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Fei L, Han R, et al. Single-cell transcriptome reveals cellular hierarchies and guides p-EMT-targeted trial in skull base chordoma. Cell Discov. 2022;8(1):94. https:\/\/doi.org\/10.1038\/s41421-022-00459-2.","journal-title":"Cell Discov"},{"issue":"2","key":"1430_CR95","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1124\/mol.105.017483","volume":"69","author":"M Jinnin","year":"2006","unstructured":"Jinnin M, Ihn H, Tamaki K. Characterization of SIS3, a novel specific inhibitor of Smad3, and its effect on transforming growth factor-\u03b21-induced extracellular matrix expression. Mol Pharmacol. 2006;69(2):597\u2013607. https:\/\/doi.org\/10.1124\/mol.105.017483.","journal-title":"Mol Pharmacol"},{"issue":"1","key":"1430_CR96","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1093\/neuonc\/noq142","volume":"13","author":"U Bogdahn","year":"2011","unstructured":"Bogdahn U, Hau P, Stockhammer G, et al. Targeted therapy for high-grade glioma with the TGF-\u03b22 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro Oncol. 2011;13(1):132\u201342. https:\/\/doi.org\/10.1093\/neuonc\/noq142.","journal-title":"Neuro Oncol"},{"issue":"23","key":"1430_CR97","doi-asserted-by":"publisher","first-page":"7189","DOI":"10.1158\/1078-0432.CCR-17-3024","volume":"25","author":"A Papachristodoulou","year":"2019","unstructured":"Papachristodoulou A, Silginer M, Weller M, et al. Therapeutic targeting of TGF\u03b2 ligands in glioblastoma using novel antisense oligonucleotides reduces the growth of experimental gliomas. Clin Cancer Res. 2019;25(23):7189\u2013201. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-3024.","journal-title":"Clin Cancer Res"},{"issue":"29","key":"1430_CR98","doi-asserted-by":"publisher","first-page":"4721","DOI":"10.1200\/JCO.2005.05.5335","volume":"24","author":"J Nemunaitis","year":"2006","unstructured":"Nemunaitis J, Dillman RO, Schwarzenberger PO, et al. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol. 2006;24(29):4721\u201330. https:\/\/doi.org\/10.1200\/JCO.2005.05.5335.","journal-title":"J Clin Oncol"},{"issue":"16","key":"1430_CR99","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1016\/j.ejca.2015.07.035","volume":"51","author":"G Giaccone","year":"2015","unstructured":"Giaccone G, Bazhenova LA, Nemunaitis J, et al. A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer. Eur J Cancer. 2015;51(16):2321\u20139. https:\/\/doi.org\/10.1016\/j.ejca.2015.07.035.","journal-title":"Eur J Cancer"},{"issue":"12","key":"1430_CR100","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1016\/S1470-2045(20)30533-7","volume":"21","author":"RP Rocconi","year":"2020","unstructured":"Rocconi RP, Grosen EA, Ghamande SA, et al. Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III\/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Oncol. 2020;21(12):1661\u201372. https:\/\/doi.org\/10.1016\/S1470-2045(20)30533-7.","journal-title":"Lancet Oncol"},{"issue":"9","key":"1430_CR101","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1001\/jamaoncol.2024.2145","volume":"10","author":"M Birrer","year":"2024","unstructured":"Birrer M, Li G, Yunokawa M, et al. Bintrafusp alfa for recurrent or metastatic cervical cancer after platinum failure: a nonrandomized controlled trial. JAMA Oncol. 2024;10(9):1204\u201311. https:\/\/doi.org\/10.1001\/jamaoncol.2024.2145.","journal-title":"JAMA Oncol"},{"issue":"12","key":"1430_CR102","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.jtho.2023.08.018","volume":"18","author":"BC Cho","year":"2023","unstructured":"Cho BC, Lee JS, Wu YL, et al. Bintrafusp alfa versus pembrolizumab in patients with treatment-naive, programmed death-ligand 1-high advanced NSCLC: a randomized, open-label, phase 3 trial. J Thorac Oncol. 2023;18(12):1731\u201342. https:\/\/doi.org\/10.1016\/j.jtho.2023.08.018.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"1430_CR103","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01045-x","volume":"14","author":"M Yi","year":"2021","unstructured":"Yi M, Zhang J, Li A, et al. The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-\u03b2 and PD-L1. J Hematol Oncol. 2021;14(1):27. https:\/\/doi.org\/10.1186\/s13045-021-01045-x.","journal-title":"J Hematol Oncol"},{"key":"1430_CR104","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1479399","volume":"15","author":"W Xu","year":"2024","unstructured":"Xu W, Xu J, Li P, et al. Discovery and preclinical evaluation of BPB-101: a novel triple functional bispecific antibody targeting GARP-TGF-\u03b2 complex\/SLC, free TGF-\u03b2 and PD-L1. Front Immunol. 2024;15:1479399. https:\/\/doi.org\/10.3389\/fimmu.2024.1479399.","journal-title":"Front Immunol"},{"issue":"25","key":"1430_CR105","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1182\/blood.2018877043","volume":"133","author":"J Volz","year":"2019","unstructured":"Volz J, Mammadova-Bach E, Gil-Pulido J, et al. Inhibition of platelet GPVI induces intratumor hemorrhage and increases efficacy of chemotherapy in mice. Blood. 2019;133(25):2696\u2013706. https:\/\/doi.org\/10.1182\/blood.2018877043.","journal-title":"Blood"},{"issue":"30","key":"1430_CR106","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abg5283","volume":"7","author":"B Saha","year":"2021","unstructured":"Saha B, Mathur T, Tronolone JJ, et al. Human tumor microenvironment chip evaluates the consequences of platelet extravasation and combinatorial antitumor-antiplatelet therapy in ovarian cancer. Sci Adv. 2021;7(30):eabg5283. https:\/\/doi.org\/10.1126\/sciadv.abg5283.","journal-title":"Sci Adv"},{"issue":"1","key":"1430_CR107","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01181-4","volume":"8","author":"L Zhao","year":"2017","unstructured":"Zhao L, Thorsheim CL, Suzuki A, et al. Phosphatidylinositol transfer protein-\u03b1 in platelets is inconsequential for thrombosis yet is utilized for tumor metastasis. Nat Commun. 2017;8(1):1216. https:\/\/doi.org\/10.1038\/s41467-017-01181-4.","journal-title":"Nat Commun"},{"issue":"3","key":"1430_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.101984","volume":"6","author":"S Wu","year":"2025","unstructured":"Wu S, Wu Z, Lu Z, et al. Selective apoptosis of tumor-associated platelets boosts the anti-metastatic potency of PD-1 blockade therapy. Cell Rep Med. 2025;6(3):101984. https:\/\/doi.org\/10.1016\/j.xcrm.2025.101984.","journal-title":"Cell Rep Med"},{"issue":"1","key":"1430_CR109","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.apsb.2021.05.012","volume":"12","author":"R Guo","year":"2022","unstructured":"Guo R, Deng M, He X, et al. Fucoidan-functionalized activated platelet-hitchhiking micelles simultaneously track tumor cells and remodel the immunosuppressive microenvironment for efficient metastatic cancer treatment. Acta Pharm Sin B. 2022;12(1):467\u201382. https:\/\/doi.org\/10.1016\/j.apsb.2021.05.012.","journal-title":"Acta Pharm Sin B"},{"issue":"7832","key":"1430_CR110","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41586-020-2850-3","volume":"587","author":"S Li","year":"2020","unstructured":"Li S, Liu M, Do MH, et al. Cancer immunotherapy via targeted TGF-\u03b2 signalling blockade in TH cells. Nature. 2020;587(7832):121\u20135. https:\/\/doi.org\/10.1038\/s41586-020-2850-3.","journal-title":"Nature"},{"key":"1430_CR111","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1376551","volume":"14","author":"T Shimizu","year":"2024","unstructured":"Shimizu T, Powderly J, Abdul Razak A, et al. First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-\u03b21 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumors. Front Oncol. 2024;14:1376551. https:\/\/doi.org\/10.3389\/fonc.2024.1376551.","journal-title":"Front Oncol"},{"issue":"2","key":"1430_CR112","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003465","volume":"10","author":"P Busenhart","year":"2022","unstructured":"Busenhart P, Montalban-Arques A, Katkeviciute E, et al. Inhibition of integrin \u03b1v\u03b26 sparks T-cell antitumor response and enhances immune checkpoint blockade therapy in colorectal cancer. J Immunother Cancer. 2022;10(2):e003465. https:\/\/doi.org\/10.1136\/jitc-2021-003465.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"1430_CR113","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-024-03250-1","volume":"44","author":"C Guo","year":"2025","unstructured":"Guo C, Sun H, Du Y, et al. Specifically blocking \u03b1v\u03b28-mediated TGF-\u03b2 signaling to reverse immunosuppression by modulating macrophage polarization. J Exp Clin Cancer Res. 2025;44(1):1. https:\/\/doi.org\/10.1186\/s13046-024-03250-1.","journal-title":"J Exp Clin Cancer Res"}],"container-title":["Human Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-026-01430-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13577-026-01430-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-026-01430-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T13:52:21Z","timestamp":1784987541000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13577-026-01430-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,25]]},"references-count":113,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["1430"],"URL":"https:\/\/doi.org\/10.1007\/s13577-026-01430-z","relation":{},"ISSN":["1749-0774"],"issn-type":[{"value":"1749-0774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,25]]},"assertion":[{"value":"15 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"116"}}